Pharmacosmos investigates anemia treatment in new patient group
A new phase III study will shed light on the efficacy of Pharmacosmos's Monoferric/Monofer in children and adolescents. This patient segment has not been eligible for the iron deficiency anemia treatment before.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Danish Pharmacosmos is on the hunt for 200 patients between the ages 0 and 18 for a clinical phase III trial involving intravenous injection treatment Monoferric, also known as Monofer, for iron deficiency anemia (IDA).